0000950170-24-027256.txt : 20240306
0000950170-24-027256.hdr.sgml : 20240306
20240306164754
ACCESSION NUMBER: 0000950170-24-027256
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240304
FILED AS OF DATE: 20240306
DATE AS OF CHANGE: 20240306
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Polymeropoulos Mihael Hristos
CENTRAL INDEX KEY: 0001355537
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34186
FILM NUMBER: 24726630
MAIL ADDRESS:
STREET 1: 9605 MEDICAL CENTER DRIVE SUITE 300
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vanda Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0001347178
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 030491827
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2200 PENNSYLVANIA AVE NW
STREET 2: SUITE 300E
CITY: WASHINGTON
STATE: DC
ZIP: 20037
BUSINESS PHONE: 202-734-3400
MAIL ADDRESS:
STREET 1: 2200 PENNSYLVANIA AVE NW
STREET 2: SUITE 300E
CITY: WASHINGTON
STATE: DC
ZIP: 20037
4
1
ownership.xml
4
X0508
4
2024-03-04
0001347178
Vanda Pharmaceuticals Inc.
VNDA
0001355537
Polymeropoulos Mihael Hristos
2200 PENNSYLVANIA AVENUE NW
SUITE 300E
WASHINGTON
DC
20037
true
true
false
true
President and CEO
Chairman of the Board
false
Common Stock
2024-03-04
4
S
false
30884
4.2438
D
1896018
D
Common Stock
2024-03-05
4
S
false
24288
4.1285
D
1871730
D
Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the default "same day sale" provisions of the RSU agreements.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.22 to $4.275, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.12 to $4.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
/s/ Mihael H. Polymeropoulos
2024-03-06